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Endocrine Disorders: Principles of Management

Capsaicin: A Therapeutic Option for Painful Diabetic Neuropathy
Karen M. Basha, BSN, RN, CDE,* and Fred W. Whitehouse, MD'

Fifteen patients with diabetes mellitus who had painful diabetic neuropalhy (PDN) were enrolled in a
double-blind .study to test the .safety and efficacy of capsaicin 0,075% (Ax.sain. Genderm. Northbrook,
IL). Twelve of the 15 patients completed the eight-week slutly. Nine trf the 12 patients reported
symptomatic relief: trf these nine, five used the drug and four used Ihe vehicle. The three patients who
reported no relief trf symptoms appUed the vehicle. Capsaicin is potentially effective when burning
pain is a major sympttmi of PDN. The side effects trf capsaicin were limited and minimal. This agent
should he considered hy clinicians for ireatmeni trf PDN. (Henry Ford Hosp Med J 1991:39:138-40)

D

iabetes mellitus (DM) affects more tiian 12 million people
in the United States and its complications are the third
leading cause of death today. All individuals with DM are susceptible lo the numerous complications of this disease.
The macrovascular and microvascular complications of DM
may lead to progressive end-organ involvement, the most painful of which is neuropathy. Clinical manifestations of painful
diabetic neuropathy (PDN) include .severe burning ofthe lower limbs and feet with nocturnal intensification (oflen occurring in a stocking-glove distribution), paresthesia, intermittent
sharp or stabbing pains, anorexia, weight loss, and depression
(1) . Of those with either long-.standing insulin-dependent diabetes mellitus (IDDM) or noninsulin-dependent diabetes mellitus
(NIDDM), 50%. will be affected by some form of neuropalhy
(2) .
Treatment of PDN includes biochemical control of the diabetic slale and appropriate pharmacologic therapy for symptomatic reliefi A variety of pharmacologic strategies are available
including oral medications, such as nonopiate anodynes, tricyclic antidepressants, phenytoin, and vitamin B (use of some of
these may be limited by systemic side effects), and local physiotherapeutics, such as transepidural neural stimulation ("TENS").
Aldose reductase inhibitors are currently being studied, but no
consensus yet exists on their efficacy and safety.
Capsaicin (Axsain, Genderm, Northbrook, IL), a recently marketed topical agent, has been used with some success in postherpefic neuralgia, post-mastectomy pain syndrome, and PDN.
We participated in a mulficenter Capsaicin Study Group and report our experience with this new agent in the treatment of PDN.

Pharmacology of Capsaicin
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an
active ingredient found in many botanical species of the night-

138

Henry Ford Hosp Med J—Vol 39, No 2, 199 i

shade family (Solanaceae). It is the chemical substance that
makes hot peppers "hot." These plants were introduced in the
15th century in Europe where they were used as a food or condiment; they were also thought lo have several medicinal properties. Cap.saicin has also played a role in folk medicine, with its
medicinal uses dating back to the 19th century. In recent years,
this substance has been available in low concentrations and used
in .several over-the-counter preparations for arthritis (3).
As a topical cream, capsaicin is marketed in two strengths.
0.025% and 0.075%. The lower strength of capsaicin was initially advised for patients with post-herpetic neuralgia. Use of
capsaicin, 0.075%, has recently been studied in clinical trials for
the treatment of post-mastectomy pain syndrome and PDN. Its
side effects include burning, slinging, and erythema at the site of
application (which usually diminishes with repeated use), dry
skin, and nasal inhalation irritant reactions. Capsaicin is thought
to deplete substance P, a pain-modulating neurotransmitter, at
the nerve terminals. Initial applications sensitize the nerve fiber
membrane to release substance P, and continued use desensitizes the membrane which subsequently reduces local concentrations of substance P. Hence, the area of capsaicin application
becomes less sensitive to pain. This decrease in pain is temporary but is sustained with repeated use of capsaicin (4). Studies
suggest that when capsaicin is di.scontinued the deplefion of
substance P slops and symptoms retum (5).
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uxxncm OF NEDRALGIA
Dermatome Affected:
(for Radiculcpathy)

Body Area A f f e c t e d :
( f o r Fteripheral Polynemx^sathy)

PATIENT
1,

INSTRUCTIONS

Apply the medication cream to painful areas of your skin FOUR TIMES A DAY l o r the
duration o l the sludy. Even if pain slops, continue medication until your iast visit to
the clinic,
ALWAYS WASH YOUR HANDS AFTER APPLICATION OF THE CREAIVl. AVOID
CONTACT WiTH YOUR EYES AND WiTH ANY OPEN WOUNDS OR iRRITATED
SKiN WHEN APPLYING THE CREAIVl, KEEP OUT OF REACH OF CHILDREN.

2,

PAIN SEVERITY

None(O)

1 1

Slight(l)

t1

Moderate (2)
[ )

Severe(3)
[ 1

When the drug is applied to normal skin, there may be mild to moderale d i s c o m f o r l
and burning or slinging sensations, especiaiiy during the firsl v^eek of Irealmenl.
Repealed applicalion usually resulls in elimination or marked decrease of this discomfort. If you so choose, you may take two |2) tablets of aspirin or acetaminophen (e,g.,
Tylenoi, Anacin-3, Datril), every four hours, for relief of the discomfort. However, if
such discomfort is too disUessing, you should call your doctor, and bolh of you will
decide whether you should continue using lhe study medication.

3,

Bring all used lubes of medication with you lo your next scheduled visit.

4,

Your doctor may consider making changes in your pain medications. If 31 any lime,
you make a change in lhe amounl or lype ot medicalion you are taking, notify your
doctor,

5,

Your doctor will schedule the clinic visits for you as toliows:

Very Severie(4)
1 ]

Fig 1—Dermatome chart used to record location of pain.

—

2 weeks after your inilial visit of the open label study

—

8 weeks afler your inillai visit

—

then every 8 weeks, up to a total of one year on the sludy

Please contaci your doctor at any time during the sludy if your pain worsens.
NOTE:

6

Your doctor will also make a telephone f o l l o w - u p
call at 4 and 6 weeks after your initial visit.

Once you finish the sludy, your doctor will call you periodically lo assess wheiher your
pain has changed after discontinuation of the study medication.

Multicenter Capsaicin Study Group
A total of 277 diabetic patients (136 IDDM and 141 NIDDM)
with PDN were randomized to an eight-week, double-blind,
placebo-controlled, multicenter clinical trial using eilher capsaicin or vehicle (placebo) to evaluate the clinical safety and efficacy of topically applied capsaicin cream (0,075%). Patients included 139 men and 138 women with a mean age of 60 years
(range 27 to 81 years). The 12 medical centers across the United
States participating in the study each randomized a mean of 20
patients (range 9 to 54) inlo one ofthe two groups.
The Henry Ford Hospital group enrolled 15 patients (9 female, 6 male) whose ages ranged from 48 to 79 years (mean 64
years). Eight patients had IDDM; seven patients had NIDDM.
The duration of DM ranged from 6 months to 24 years (mean
12 years). Twelve of the patients had peripheral polyneuropathy
and three had radiculopathy. The duration of the symptomatic
neuralgia ranged from 2 months lo 15 years (mean 4 years).
Inclusion criteria included: I) individuals wilh IDDM or
NIDDM belween ages 18 to 85 years; 2) a fasting blood glucose
< 180 mg/dL or a glycosylated hemoglobin < 11%; 3) presence
of either clinical peripheral polyneuropathy or radiculopathy,
characterized by local pain and paresthesia confirmed by findings on electromyogram (EMG); 4) pain interfering with daily
activities and/or sleep at least some of the time; 5) other topical
medications applied to the affected areas discontinued at least
seven days prior to study entry; 6) all oral medications for pain
associated with neuropathy continued but without change in
dosage or frequency of administration; 7) medication prescribed
for indications other than pain could be initiated provided their
use did not interfere with the evaluation of the study drug. Informed conseni was obtained from all participanls in the study.
Exclusion criteria included; I) females who were pregnant or
lactating; 2) patients who had open lesions on the affected skin
area; 3) individuals with a serious medical or psychiatric disease.
Before randomization at a pretreatment visit, the history was
obtained and directed neurological examination performed.

Henry Ford Hosp Med J—Vol 39, No 2, 1991

Fig 2—Patient instructiemsfrn-the application erf study medication to the affected areas.

Nerve conduction was studied in patients who had not had the
test in the previous six months. EMG, used at the onset of the
study to confirm the diagnosis of PDN, was not repeated. The
anatomical distribution of the pain was recorded on a dermatome chart (Fig 1).
Patients were randomly assigned into one of two study groups
ulilizing eilher capsaicin or a vehicle and were instructed lo apply the cream to the affected area four times daily. Each patient
was informed ofthe possible side effects of capsaicin and given
an instruction sheet to follow (Fig 2). Instructions were reviewed
and questions and concerns regarding the protocol were discussed with the patient prior to leaving the clinic.
The side effects of capsaicin included mild to moderate buming or stinging when applied to the affected area. If side effects
occurred, patients were instructed to lake two tablets of aspirin
or acetaminophen every four hours. If symptoms were severe,
patients were instructed to contact the clinic promptly lo determine ifthe study drug should be discontinued. Each patient was
also instructed to avoid contact with their eyes and mucous
membranes when applying the cream and to wash their hands
after each use. Al baseline and at weeks 2, 4, 6, and 8, pain was
assessed by the patient and nurse coordinator using three standard pain scales; physician global evaluation (PGE), visual analogue scale for pain intensity (VAS-P), and visual analogue scale
for pain relief (VAS-R). The PGE was completed by the nurse
coordinator and physician with input from the patient to assess
changes in pain severity compared to baseline. The other two
scales were completed by the patient. Patients were instructed to
complete these questionnaires based on the time or times of the
day the pain was most intense.
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Patients Randomized
(15)

drop out (3)

Capsaicin (2) vehicle (1)

completed study (12)

relief (9)

No relief (3)

Capsaicin (5) vehicle (4)

vehicle (3)

Fig 3—Schemafrn-double-blind capsaicin studv.

Results
Ofthe 15 patients enrolled in the Henry Ford Hospital group,
seven used capsaicin and eight u.sed the vehicle cream during
the study period. Twelve patients completed the trial; of the
three patients who dropped out, two did so because of severe
burning (1 capsaicin, I vehicle) and one because of treatment
failure (capsaicin). Nine patients reported moderate lo complete
relief of pain during the trial (5 capsaicin. 4 vehicle), and three
patients reported no relief (all vehicle) (Fig 3).

Discussion
The results of the multicenter Capsaicin Study Group demonstrate that capsaicin offers symptomatic relief in the treatment
of PDN and radiculopathy (6). Thesefindingswere based on the
analyses of the efficacy parameters (i.e., PGE, VAS-P, VAS-R).
Of the 277 patients randomized nationally, 138 received capsaicin and 139 received vehicle. Based on the final visit analyses
of standard pain scales, 69.5% of the patients in the capsaicin
group and 53.4% of the patients in the vehicle group reporied
improvement in pain (PGE) (P < 0.012). A total of 38.1 % of the
patients in the capsaicin group and 27.1% in the vehicle group
reported a decrease in pain intensity (VAS-P) (P < 0.037). Finally. 58.4% of the cap.saicin group and 45.3% of the vehicle
group reported they had a relief of pain (VAS-R) (P < 0.004). All
of these are significanl at the 5% level (6).
In lighl of the overallfindingsof the multicenter group, we
feel that capsaicin is worthy of consideration in the treatment of
PDN. The placebo respon.se, not uncommon in pain studies, can
be attributed lo the following factors; scheduled visits to talk
with the patient regarding pain, patient response to the placebo
effeci, and rubbing the area .skin with lanolin ointment which increases the local blood supply and is soothing to the skin.
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Capsaicin is indicated in patients whose primary complaint
from neuropalhy is pain. Most patients whose symptoms improved with capsaicin reported buming pain as a primary complaint. The drug has not yet been studied in patients whose primary complaint is numbness or dysesthesia. A few patients with
localized sensory mononeuropathy (intercostal and truncal neuropathy or meralgia paresthetica) may also benefit from its use.
The goal of therapy, symptomatic relief, should occur two to
six weeks after beginning therapy. Therapy is instituted with
0.025% capsaicin applied to the affected area four times daily.
Ifno response is achieved, we advise the more concentrated
form of 0.075% four times daily. Once relief is obtained, frequency of use can be adjusted to maintain symptom control according to individual need.
The advantages of capsaicin are; 1) application directly to the
affected area, 2) no systemic effects, and 3) diminished local
side effects with repeated use of the cream. Disadvantages include: 1) local side effects at the site ofapplication, which, if
.severe, may require discontinuation of the medication; 2) high
costof treatment ($53 to $55 for a 45-gram tube of capsaicin at
the 0.075% strength and an average of $35 for a 45-gram tube
at the 0.025% strength, with each tube permitting two to three
weeks of therapy when used as advised); and 3) possible use
without medical advice as patients may obtain it over-the-counter without a prescription. If local burning pain is a primary
complaint of patients with diabetic neuropathy, the use of capsaicin merits a trial. Of course, this medication is not used in the
presence of skin ulcers or infection. Although the results in our
small sample of patients are not decisive, the multicenter report
persuades us that the agent has therapeutic benefit. The frequency of relief by vehicle cream (in our experience as well as
in the multicenter study) emphasizes the need for double-blind
studies when assessing clinical effectiveness.
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